NASDAQ:NBSE NeuBase Therapeutics (NBSE) Stock Forecast, Price & News $0.18 0.00 (0.00%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$0.17▼$0.1850-Day Range$0.13▼$0.2152-Week Range$0.12▼$1.45Volume137,957 shsAverage Volume436,879 shsMarket Capitalization$6.02 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability NeuBase Therapeutics MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside6,076.3% Upside$11.00 Price TargetShort InterestHealthy2.00% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.40) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 stars 3.0 Analyst's Opinion Consensus RatingNeuBase Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, NeuBase Therapeutics has a forecasted upside of 6,076.3% from its current price of $0.18.Amount of Analyst CoverageNeuBase Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.00% of the float of NeuBase Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeuBase Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeuBase Therapeutics has recently increased by 0.71%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNeuBase Therapeutics does not currently pay a dividend.Dividend GrowthNeuBase Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeuBase Therapeutics has received a 78.18% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for NeuBase Therapeutics is -0.61. Previous Next 2.0 News and Social Media Coverage News SentimentNeuBase Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.Search Interest14 people have searched for NBSE on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeuBase Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.70% of the stock of NeuBase Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 37.21% of the stock of NeuBase Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NeuBase Therapeutics are expected to grow in the coming year, from ($0.40) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeuBase Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeuBase Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuBase Therapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NeuBase Therapeutics (NASDAQ:NBSE) StockNeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm's therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.Read More Receive NBSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NBSE Stock News HeadlinesMay 24, 2023 | finance.yahoo.comNeuBase to Participate in Jefferies Healthcare ConferenceMay 22, 2023 | msn.comNeuBase Releases Promising Preclinical Data From Stealth Editors To Achieve Gene EditingJune 1, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 22, 2023 | finance.yahoo.comNeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™May 16, 2023 | finance.yahoo.comNeuBase Announces Formation of Gene Editing Advisory BoardMay 12, 2023 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Reports Business Update and Financial Results for the First Quarter of 2023May 11, 2023 | msn.comNeuBase Therapeutics GAAP EPS of -$0.12 misses by $0.02May 11, 2023 | finance.yahoo.comNeuBase Reports Business Update and Financial Results for the First Quarter of 2023June 1, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 2, 2023 | finance.yahoo.comNeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual MeetingApril 29, 2023 | americanbankingnews.comNeuBase Therapeutics, Inc. (NASDAQ:NBSE) Short Interest Up 35.5% in AprilApril 20, 2023 | msn.comWhy MIND Technology Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving PremarketMarch 27, 2023 | msn.comWhy Motorsport Games Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving PremarketFebruary 15, 2023 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023February 14, 2023 | finance.yahoo.comNeuBase Therapeutics Reports Business Update and Financial Results for the First Quarter of Fiscal Year 2023December 29, 2022 | finance.yahoo.comNeuBase Therapeutics selling stake in company to New York investment firm Alumni CapitalDecember 21, 2022 | finanznachrichten.deNeuBase Therapeutics, Inc.: NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022December 21, 2022 | nz.finance.yahoo.comNeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022December 21, 2022 | finance.yahoo.comNeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2022October 24, 2022 | bizjournals.comNeuBase Therapeutics to lose presidentOctober 21, 2022 | bizjournals.comNeuBase reaches research agreement on gene-editing platformOctober 21, 2022 | finance.yahoo.comNeuBase Therapeutics Announces Gene Editing Research Agreement with Global Healthcare CompanyOctober 17, 2022 | finance.yahoo.comNeuBase Lays Off 60% Of Workforce, Reprioritizes Pipeline To Focus On Gene Editing TechOctober 17, 2022 | bizjournals.comNeuBase Therapeutics begins strategic restructuringOctober 14, 2022 | nasdaq.comNeuBase Therapeutics Announces Restructuring Plan; To Cut Workforce By About 60%October 14, 2022 | seekingalpha.comNeuBase Therapeutics announces restructuring, to cut 60% of workforceOctober 14, 2022 | finance.yahoo.comNeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene EditingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NBSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NBSE Company Calendar Last Earnings5/11/2023Today6/01/2023Next Earnings (Estimated)8/10/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NBSE CUSIPN/A CIK1173281 Webwww.neubasetherapeutics.com Phone(164) 645-1790FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+4,672.6%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-114.12% Return on Assets-82.14% Debt Debt-to-Equity RatioN/A Current Ratio7.40 Quick Ratio7.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book0.41Miscellaneous Outstanding Shares33,810,000Free Float27,826,000Market Cap$6.02 million OptionableNot Optionable Beta1.01 Key ExecutivesDietrich A. StephanChief Executive Officer & DirectorTodd P. BranningChief Financial OfficerCurt W. BradshawChief Scientific OfficerAnthony RossomandoChief Technology OfficerRon SarkarVice President-Business DevelopmentKey CompetitorsOragenicsNYSE:OGENPhio PharmaceuticalsNASDAQ:PHIOSynaptogenixNASDAQ:SNPXEvoke PharmaNASDAQ:EVOKPetros PharmaceuticalsNASDAQ:PTPIView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 112,593 shares on 5/12/2023Ownership: 0.521%Simplex Trading LLCBought 500 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions NBSE Stock - Frequently Asked Questions Should I buy or sell NeuBase Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuBase Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NBSE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NBSE, but not buy additional shares or sell existing shares. View NBSE analyst ratings or view top-rated stocks. What is NeuBase Therapeutics' stock price forecast for 2023? 3 analysts have issued 12 month target prices for NeuBase Therapeutics' stock. Their NBSE share price forecasts range from $7.00 to $15.00. On average, they anticipate the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 6,076.3% from the stock's current price. View analysts price targets for NBSE or view top-rated stocks among Wall Street analysts. How have NBSE shares performed in 2023? NeuBase Therapeutics' stock was trading at $0.1902 at the beginning of the year. Since then, NBSE shares have decreased by 6.4% and is now trading at $0.1781. View the best growth stocks for 2023 here. When is NeuBase Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our NBSE earnings forecast. How were NeuBase Therapeutics' earnings last quarter? NeuBase Therapeutics, Inc. (NASDAQ:NBSE) announced its quarterly earnings results on Thursday, May, 11th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.02. What other stocks do shareholders of NeuBase Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN), Pfizer (PFE), VBI Vaccines (VBIV), AbbVie (ABBV) and Aravive (ARAV). What is NeuBase Therapeutics' stock symbol? NeuBase Therapeutics trades on the NASDAQ under the ticker symbol "NBSE." Who are NeuBase Therapeutics' major shareholders? NeuBase Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.52%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Dietrich A Stephan, Eric I Richman, Todd P Branning and William Roland Mann. View institutional ownership trends. How do I buy shares of NeuBase Therapeutics? Shares of NBSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NeuBase Therapeutics' stock price today? One share of NBSE stock can currently be purchased for approximately $0.18. How much money does NeuBase Therapeutics make? NeuBase Therapeutics (NASDAQ:NBSE) has a market capitalization of $6.02 million. The company earns $-33,780,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. How can I contact NeuBase Therapeutics? NeuBase Therapeutics' mailing address is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. The official website for the company is www.neubasetherapeutics.com. The company can be reached via phone at (164) 645-1790 or via email at daniel@lifesciadvisors.com. This page (NASDAQ:NBSE) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuBase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.